Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab

BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. METHODS: A retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Kyu-Hyoung, Yoon, Ho-Il, Kang, Young Ae, Lee, Keun-Wook, Kim, Jee Hyun, Bang, Soo-Mee, Lee, Jae Ho, Lee, Choon-Taek, Lee, Jong Seok
Formato: Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829422/
https://www.ncbi.nlm.nih.gov/pubmed/20195409
http://dx.doi.org/10.3904/kjim.2010.25.1.86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829422/
https://www.ncbi.nlm.nih.gov/pubmed/20195409
http://dx.doi.org/10.3904/kjim.2010.25.1.86

Ejemplares similares